✦ LIBER ✦

Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer

✍ Scribed by Innocenti, F.; Schilsky, R. L.; Ramirez, J.; Janisch, L.; Undevia, S.; House, L. K.; Das, S.; Wu, K.; Turcich, M.; Marsh, R.; Karrison, T.; Maitland, M. L.; Salgia, R.; Ratain, M. J.

Book ID: 126210148
Publisher: American Society of Clinical Oncology
Year: 2014
Tongue: English
Weight: 141 KB
Volume: 32
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2014.55.2307

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genotype-directed, dose-finding study of

Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms

✍ Taroh Satoh; Takashi Ura; Yasuhide Yamada; Kentaro Yamazaki; Toshimasa Tsujinaka 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Phase II and UGT1A1 genotype study of ir

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer

✍ Jo, J-C; Lee, J-L; Ryu, M-H; Chang, H M; Kim, M; Lee, H J; Kim, H-S; Shin, J-G; 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 357 KB

Prognostic advantage of irinotecan dose

Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting

✍ Lu, Chien-Yu; Huang, Ching-Wen; Hu, Huang-Ming; Tsai, Hsiang-Lin; Huang, Chun-Mi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 455 KB

The genotyping of UGT1A1 polymorphism fo

The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen

✍ Lu, Chien-Yu; Tsai, Hsiang-Lin; Wang, Jaw-Yuan 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 169 KB

The Role of UGT1A1*28 Polymorphism in th

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

✍ Toffoli, G. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 104 KB

PMD44 Economic Evaluation of the UGT1A1

PMD44 Economic Evaluation of the UGT1A1 Pharmacogenetic Test to inform Dose Selection of Irinotecan-Based Chemotherapy

✍ F.H. Shabaruddin; R.A. Elliott; P. Tappenden; K. Payne 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB